Skin cancer diagnostic company AI Medical Technology raises SEK12m (US$1m) via an oversubscribed bridge financing round in anticipation of a significant Series A later this year
Stockholm, Sweden, April 29, 2024. AI Medical Technology today announced the successful closure of an oversubscribed bridge financing round worth SEK12 (US$1m). Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders.The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis of malignant melanomas. Results from a prospective, multicentre, peer-reviewed clinical trial recently published in the British Journal of